International Journal of Radiation Oncology * Biology * Physics
Volume 78, Issue 3 , Pages 751-758 , 1 November 2010

Phase II Trial of Combined High-Dose-Rate Brachytherapy and External Beam Radiotherapy for Adenocarcinoma of the Prostate: Preliminary Results of RTOG 0321

  • I-Chow Hsu, M.D.

      Affiliations

    • University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
    • Corresponding Author InformationReprint requests to: I.-Chow Joe Hsu, M.D., Department of Radiation Oncology, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St., H1031, San Francisco, CA 94143-1708. Tel: (415) 353-7175; Fax: (415) 353-9883
    • ,
  • Kyounghwa Bae, Ph.D.

      Affiliations

    • Department of Statistics, Radiation Therapy Oncology Group, Philadelphia, PA
    • ,
  • Katsuto Shinohara, M.D.

      Affiliations

    • University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
    • ,
  • Jean Pouliot, Ph.D.

      Affiliations

    • University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
    • ,
  • James Purdy, Ph.D.

      Affiliations

    • Image-Guided Therapy Quality Assurance Center, St. Louis, MO
    • ,
  • Geoffrey Ibbott, Ph.D.

      Affiliations

    • Radiological Physics Center, University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Joycelyn Speight, M.D., Ph.D.

      Affiliations

    • University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
    • ,
  • Eric Vigneault, M.D.

      Affiliations

    • L'Hotel-Dieu De Quebec, Quebec, QC, Canada
    • ,
  • Robert Ivker, M.D.

      Affiliations

    • Newark Beth Israel Medical Center, Newark, NJ
    • ,
  • Howard Sandler, M.D.

      Affiliations

    • University of Michigan, Ann Arbor, MI

Received 21 May 2009 ,Revised 29 July 2009 ,Accepted 21 August 2009.

References 

  1. Hsu I-C, Pickett B, Shinohara K, et al. Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: Potential for dose escalation. Int J Radiat Oncol Biol Phys. 2000;46:851–858
  2. Brenner D, Hall E. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  3. D'Souza WD, Thames HD. Is the alpha/beta ratio for prostate cancer low?. [Comment on Int J Radiat Oncol Biol Phys 2001;51:213–214 UI: 21407968] Int J Radiat Oncol Biol Phys. 2001;51:1–3
  4. Duchesne GM, Peters LJ. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy [editorial]. Int J Radiat Oncol Biol Phys. 1999;44:747–748
  5. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys. 2001;50:1021–1031
  6. Borghede G, Hedelin H, Holmäng S, et al. Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma. Radiother Oncol. 1997;44:237–244
  7. Dinges S, Deger S, Koswig S, et al. High-dose rate interstitial with external beam irradiation for localized prostate cancer—Results of a prospective trial. Radiother Oncol. 1998;48:197–202
  8. Martinez A, Gonzalez J, Stromberg J, et al. Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial. Int J Radiat Oncol Biol Phys. 1995;33:1019–1027
  9. Mate T, Gottesman J. Fractionated HDR conformal prostate brachytherapy. Presented at the 8th International Brachytherapy Conference, Nice, France, November 25–28, 1995. Veenendaal, The Netherlands: Nucletron International BV; 1995;pp 75–78
  10. Kovács G, Galalae R, Loch T, et al. Prostate preservation by combined external beam and HDR brachytherapy in nodal negative prostate cancer. Strahlenther Onkol. 1999;175(Suppl. 2):87–88
  11. Galalae RM, Kovacs G, Schultze J, et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 2002;52:81–90
  12. Kovacs G, Wirth B, Bertermann H, et al. Prostate preservation by combined external beam and HDR brachytherapy at nodal negative prostate cancer patients—An intermediate analysis after ten years' experience. Int J Radiat Oncol Biol Phys. 1996;36:198
  13. Mate TP, Gottesman JE, Hatton J, et al. High dose-rate afterloading 192Iridium prostate brachytherapy: Feasibility report. Int J Radiat Oncol Biol Phys. 1998;41:525–533
  14. Martinez AA, Pataki I, Edmundson G, et al. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: A feasibility report. Int J Radiat Oncol Biol Phys. 2001;49:61–69
  15. Martinez AA, Kestin LL, Stromberg JS, et al. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: The William Beaumont phase II dose-escalating trial. Int J Radiat Oncol Biol Phys. 2000;47:343–352
  16. Martinez A, Gonzalez J, Spencer W, et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol. 2003;169:974–980
  17. Vargas CE, Martinez AA, Boike TP, et al. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: Results of a phase I to II study. Int J Radiat Oncol Biol Phys. 2006;66:416–423
  18. Vargas C, Martinez A, Galalae R, et al. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features. Prostate Cancer Prostatic Dis. 2006;9:245–253
  19. International Commission on Radiological Units. ICRU report 58: Dose and volume specification for reporting interstitial therapy. Bethesda: International Commission on Radiation Units and Measurements; 1997;
  20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  21. Lee WR, DeSilvio M, Lawton C, et al. A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: Preliminary results of RTOG P-0019. Int J Radiat Oncol Biol Phys. 2006;64:804–809
  22. Lee WR, Bae K, Lawton C, et al. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: Analysis of Radiation Therapy Oncology Group study 0019. Cancer. 2007;109:1506–1512
  23. Hurwitz MD, Halabi S, Ou SS, et al. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: An initial report of CALGB 99809. Int J Radiat Oncol Biol Phys. 2008;72:814–819
  24. Hoskin PJ, Motohashi K, Bownes P, et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial. Radiother Oncol. 2007;84:114–120
  25. Damore S, Syed N, Puthawala A, et al. Needle displacement during HDR brachytherapy in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 2000;46:1205–1211
  26. Hoskin PJ, Bownes PJ, Ostler P, et al. High dose rate afterloading brachytherapy for prostate cancer: catheter and gland movement between fractions. Radiother Oncol. 2003;68:285–288
  27. Mullokandov E, Gejerman G. Analysis of serial CT scans to assess template and catheter movement in prostate HDR brachytherapy. Int J Radiat Oncol Biol Phys. 2004;58:1063–1071
  28. Kim Y, Hsu IC, Pouliot J. Measurement of craniocaudal catheter displacement between fractions in computed tomography-based high dose rate brachytherapy of prostate cancer. J Appl Clin Med Phys. 2007;8:2415

 Supported by Grants RTOG U10 CA21661, CCOP U10 CA37422, Stat U10 CA32115 and U24 CA81647 from the National Cancer Institute, Rockville, MD.

 This manuscript's contents are the sole responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

 Conflict of interest: none.

PII: S0360-3016(09)03028-4

doi: 10.1016/j.ijrobp.2009.08.048

International Journal of Radiation Oncology * Biology * Physics
Volume 78, Issue 3 , Pages 751-758 , 1 November 2010

Article Tools

* Image Usage & Resolution